Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Celecoxib

FDA-approved product (capsule, oral), marketed as Celebrex, Celecoxib, Elyxyb and 1 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Celecoxib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Ankylosing spondylitis
  • Cancer
  • Colorectal neoplasm
  • Dysmenorrhea
  • Familial adenomatous polyposis
  • Familial adenomatous polyposis 1
  • Hemorrhage
  • Juvenile idiopathic arthritis
  • Migraine disorder
  • Neoplasm
  • Osteoarthritis
  • Pain
  • Peptic ulcer
  • Peptic ulcer disease
  • Rheumatic disease
  • Rheumatoid arthritis
  • and 2 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents; Coxibs
FDA pharmacologic class
Nonsteroidal Anti-inflammatory Drug FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli25.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis87.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 1 of 1 lab record
Open Celecoxib in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Celecoxib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

    NCT07632235 · start 2026-09-15

    Registered record
    Registry ID
    NCT07632235
    Conditions
    Intrahepatic Cholangiocarcinoma (Icc)
    Interventions
    Celecoxib + Pembrolizumab + Gemcitabine/Cisplatin; Pembrolizumab + Gemcitabine/Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-15
    Completion
    2030-12-31
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntrahepatic Cholangiocarcinoma (Icc)
    InterventionCelecoxib + Pembrolizumab + Gemcitabine/Cisplatin; Pembrolizumab + Gemcitabine/Cisplatin
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients

    NCT07809893 · start 2026-08-10

    Registered record
    Registry ID
    NCT07809893
    Conditions
    Colorectal Cancer
    Interventions
    Ivonescimab +mFOLFOXIRI +celecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-08-10
    Completion
    2028-06-30
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionIvonescimab +mFOLFOXIRI +celecoxib
    PhasePhase 2
    Registry statusRecruiting

  • A Phase I Study of KLA318-2 Nanocrystal Injection

    NCT07171034 · start 2025-09-01

    Registered record
    Registry ID
    NCT07171034
    Conditions
    Healthy Participants
    Interventions
    KLA318-2 Nanocrystal Injection; Celebrex Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2025-09-01
    Completion
    2026-05-31
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionKLA318-2 Nanocrystal Injection; Celebrex Capsule
    PhasePhase 1
    Registry statusRecruiting

  • Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer

    NCT06903858 · start 2025-06-01

    Registered record
    Registry ID
    NCT06903858
    Conditions
    Colorectal Cancer; Microsatellite Instability High; Mismatch Repair Deficiency
    Interventions
    Toripalimab plus celecoxib; Non-operative management; Curative-intent surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-06-01
    Completion
    2031-04-01
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Microsatellite Instability High; Mismatch Repair Deficiency
    InterventionToripalimab plus celecoxib; Non-operative management; Curative-intent surgery
    PhasePhase 2
    Registry statusRecruiting

  • Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis

    NCT06545526 · start 2024-08-13

    Registered record
    Registry ID
    NCT06545526
    Conditions
    Familial Adenomatous Polyposis
    Interventions
    celecoxib monotherapy; celecoxib and metformin combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2024-08-13
    Completion
    2026-06-30
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFamilial Adenomatous Polyposis
    Interventioncelecoxib monotherapy; celecoxib and metformin combination
    PhasePhase 3
    Registry statusUnknown

  • Multimodal Pain Package vs. Regular Formulation for Pain Management in Ambulatory Spinal Surgery

    NCT05965492 · start 2024-06-01

    Registered record
    Registry ID
    NCT05965492
    Conditions
    Spinal Disorder
    Interventions
    Acetaminophen; Celebrex; Gabapentin; Famotidine; Decadron; Oxycodone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2024-06-01
    Completion
    2025-06-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Disorder
    InterventionAcetaminophen; Celebrex; Gabapentin; Famotidine +2 more
    PhasePhase 3
    Registry statusWithdrawn

  • Metformin Safety and Efficacy in Osteoarthritis.

    NCT06231758 · start 2024-01-30

    Registered record
    Registry ID
    NCT06231758
    Conditions
    Osteo Arthritis Knee
    Interventions
    Celecoxib 200mg; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-01-30
    Completion
    2027-11-20
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteo Arthritis Knee
    InterventionCelecoxib 200mg; Metformin
    PhasePhase 3
    Registry statusRecruiting

  • Efficacy and Safety of Ningmitai Capsule Alone or Combined With Celecoxib in the Treatment of CP/CPPS

    NCT06159114 · start 2023-12-19

    Registered record
    Registry ID
    NCT06159114
    Conditions
    Chronic Prostatitis
    Interventions
    Ningmitai capsule; Celecoxib capsule; Ningmitai placebo; Celecoxib placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-12-19
    Completion
    2025-01-31
    Enrolment
    242

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Prostatitis
    InterventionNingmitai capsule; Celecoxib capsule; Ningmitai placebo; Celecoxib placebo
    PhasePhase 4
    Registry statusCompleted

  • How to Reduce Pain in Patients Undergoing Office Hysteroscopy.

    NCT05911126 · start 2023-06-13

    Registered record
    Registry ID
    NCT05911126
    Conditions
    Pain
    Interventions
    Celecoxib 200 mg, Hyoscine-N-butyl bromide (HBB), placebo tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-06-13
    Completion
    2023-12-13
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain
    InterventionCelecoxib 200 mg, Hyoscine-N-butyl bromide (HBB), placebo tablet
    PhaseNot applicable
    Registry statusUnknown

  • Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

    NCT05731726 · start 2023-02-22

    Registered record
    Registry ID
    NCT05731726
    Conditions
    pMMR; MSS; MSI-L; Locally Advanced Rectal Carcinoma
    Interventions
    Serplulimab; Capecitabine; Oxaliplatin; Celecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-02-22
    Completion
    2026-12-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionpMMR; MSS; MSI-L; Locally Advanced Rectal Carcinoma
    InterventionSerplulimab; Capecitabine; Oxaliplatin; Celecoxib
    PhasePhase 2
    Registry statusRecruiting

  • Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)

    NCT05085574 · start 2023-02-07

    Registered record
    Registry ID
    NCT05085574
    Conditions
    2019 Novel Coronavirus Disease; 2019 Novel Coronavirus Infection; 2019-nCoV Disease; 2019-nCoV Infection; COVID-19 Pandemic; COVID-19 Virus Disease; COVID-19 Virus Infection; Covid19; Coronavirus Disease 2019; SARS-CoV-2 Infection; SARS-CoV-2 Acute Respiratory Disease; COVID-19
    Interventions
    Famotidine; Celecoxib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2023-02-07
    Completion
    2023-02-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Condition2019 Novel Coronavirus Disease; 2019 Novel Coronavirus Infection; 2019-nCoV Disease; 2019-nCoV Infection +8 more
    InterventionFamotidine; Celecoxib; Placebo
    PhasePhase 2
    Registry statusWithdrawn

  • Preoperative Gabapentin vs Placebo for Vaginal Prolapse Surgery

    NCT05658887 · start 2023-01-01

    Registered record
    Registry ID
    NCT05658887
    Conditions
    Pelvic Organ Prolapse; Perioperative/Postoperative Complications
    Interventions
    Gabapentin; Gabapentin Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-01-01
    Completion
    2024-12-31
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPelvic Organ Prolapse; Perioperative/Postoperative Complications
    InterventionGabapentin; Gabapentin Placebo
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of Clinical Efficacy of Herbal Compound in the Treatment of NSLBP

    NCT06336993 · start 2022-01-01

    Registered record
    Registry ID
    NCT06336993
    Conditions
    Low Back Pain
    Interventions
    herbal compound; Celecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-01-01
    Completion
    2023-12-15
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow Back Pain
    Interventionherbal compound; Celecoxib
    PhasePhase 4
    Registry statusCompleted

  • Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis

    NCT05324163 · start 2021-09-29

    Registered record
    Registry ID
    NCT05324163
    Conditions
    KNEE OSTEOARTHRITIS
    Interventions
    X0002 Spray; Celecoxib capsules; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-09-29
    Completion
    2023-02-06
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKNEE OSTEOARTHRITIS
    InterventionX0002 Spray; Celecoxib capsules; placebo
    PhasePhase 3
    Registry statusCompleted

  • ERAS in Autologous Breast Reconstruction: A Pilot RCT

    NCT04306003 · start 2019-11-05

    Registered record
    Registry ID
    NCT04306003
    Conditions
    Breast Cancer
    Interventions
    ERAS pathway; Standard Perioperative Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-11-05
    Completion
    2020-06-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionERAS pathway; Standard Perioperative Care
    PhaseNot applicable
    Registry statusCompleted